Wendy Stock to Clinical Trials as Topic
This is a "connection" page, showing publications Wendy Stock has written about Clinical Trials as Topic.
Connection Strength
1.300
-
Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. Blood Adv. 2022 07 26; 6(14):4085-4092.
Score: 0.517
-
Clinical trials in adult AML. Clin Adv Hematol Oncol. 2009 Jun; 7(6):8-10.
Score: 0.208
-
Impact of modernizing eligibility criteria on enrollment and representation in acute myeloid leukemia clinical trials. Blood. 2026 Feb 05; 147(6):639-649.
Score: 0.165
-
Inclusion of Adolescents and Young Adults in Cancer Clinical Trials. Semin Oncol Nurs. 2015 Aug; 31(3):197-205.
Score: 0.078
-
Children, adolescents, and young adults with leukemia: the empty half of the glass is growing. J Clin Oncol. 2012 Nov 10; 30(32):4037-8; author reply 4038-9.
Score: 0.065
-
Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma. 2010 Feb; 51(2):188-98.
Score: 0.054
-
Burkitt lymphoma/leukemia: improving prognosis. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S231-8.
Score: 0.050
-
Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults. Curr Hematol Malig Rep. 2008 Jul; 3(3):144-51.
Score: 0.049
-
New Approaches to Treating Challenging Subtypes of ALL in AYA Patients. Curr Hematol Malig Rep. 2020 12; 15(6):424-435.
Score: 0.029
-
Treatment of Acute Promyelocytic Leukemia in Adults. J Oncol Pract. 2018 11; 14(11):649-657.
Score: 0.025
-
Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018 04; 53(4):449-456.
Score: 0.024
-
Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia. Leuk Lymphoma. 2016 07; 57(7):1527-33.
Score: 0.021
-
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant. 2010 Oct; 16(10):1325-46.
Score: 0.014